The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis

Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971 Folkman J, Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992 Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K, Benezra R: Id1 and Id3 are required for neurogenesis, angiogenesis, vascularization of tumour xenografts. Nature 401: 670-677, 1999 Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996 Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424, 1998 Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21: 505-515, 2000. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095-1104, 1991 Folkman J, Klagsburn M: Angiogenic factors. Science 235: 442-447, 1987 Brem S: Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control 6: 436-458, 1999 Pepper MS, Montesano R: Proteolytic balance and capillary morphogenesis. Cell Differ Dev 32: 319-327, 1990 Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD: Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49: 138-162, 1996 Paku S, Paweletz N: First steps of tumor-related angiogenesis. Lab Invest 65: 334-346, 1991 Paku S: Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 4: 62-75, 1998 Pintucci G, Bikfalvi A, Klein S, Rifkin DB: Angiogenesis and the fibrinolytic system. Semin Thromb Hemost 22: 517-524, 1996 Pluda JM: Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Semin Oncol 24: 203-218, 1997 Diaz-Flores L, Gutierrez R, Varela H: Angiogenesis: An update. Histol Histopathol 9: 807-843, 1994 D'Amore PA: Capillary growth: A two-cell system. Semin Cancer Biol 3: 49-56, 1992 Hirschi KK, D'Amore PA: Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS 79: 419-428, 1997 Nehls V, Denzer K, Drenckhahn D: Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res 270: 469-474, 1992 Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995 Beck LJ, D'Amore PA: Vascular development: Cellular and molecular regulation. FASEB J 11: 365-373, 1997 Poole TJ, Coffin JD: Vasculogenesis and angiogenesis: Two distinct morphogenetic mechanisms establish embryonic vascular pattern. J Exp Zool 251: 224-231, 1989 Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, Kemler R, Doetschman T: Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102: 471-478, 1988 Pardanaud L, Yassine F, Dieterlen-Lievre F: Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian ontogeny. Development 105: 473-485, 1989 Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 andAC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95: 952-958, 2000 Rafii S: Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 105: 17-19, 2000 Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967, 1997 Folkman J: Angiogenesis, angiogenesis inhibition: An overview. EXS 79: 1-8, 1997 Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2539, 1996 Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995 Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992 Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Humanangiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997 O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997 Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA: The mechanism of cancermediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 94: 10868-10872, 1997 Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291, 1998 Denekamp J, Hill SA, Hobson B: Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19: 271-275, 1983 Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000 Masferrer JL, Koki A, Seibert K: COX-2 inhibitors. A new class of antiangiogenic agents. Ann NY Acad Sci 889: 84-86, 1999. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97-120, 1998 Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000 DuBois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J, 12: 1063-1073, 1998 Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T: Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 269: 11769-11775, 1994 Perkins DJ, Kniss DA: Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amnion-derived WISH cells. Biochem J 321(Pt 3): 677-681, 1997 Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD: Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 275: 6628-6635, 2000 Diaz A, Chepenik KP, Korn JH, ReginatoAM, Jimenez SA: Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241: 222-229, 1998 Perkins DJ, Kniss DA: Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs. Prostaglandins 54: 727-743, 1997 Peterson HI: Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res 6: 251-253, 1986 Deutsch TA, Hughes WF: Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol 87: 536-540, 1979 Parke A, Bhattacherjee P, Palmer RM, Lazarus NR: Characterization and quantification of copper sulfateinduced vascularization of the rabbit cornea. Am J Pathol 130: 173-178, 1988 Ziche M, Jones J, Gullino PM: Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 69: 475-482, 1982 Davel LE, Miguez MM, de Lustig ES: Evidence that indomethacin inhibits lymphocyte-induced angiogenesis. Transplantation 39: 564-565, 1985 Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423, 1999 Golab J, Kozar K, Kaminski R, Czajka A, Marczak M, Switaj T, Giermasz A, Stoklosa T, Lasek W, Zagozdzon R, Mucha K, Jakobisiak M: Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci 66: 1223-1230, 2000 Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803-809, 1996 Nishimura G, Yanoma S, Mizuno H, Kawakami K, Tsukuda M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90: 1152-1162, 1999 Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R: Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20: 1939-1944, 1999 Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412, 1998 Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, Kitayama W, Wakabayashi K, Konishi Y: Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-([4]-hydroxybutyl)nitrosamine. Cancer Res 58: 3028-3031, 1998 Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 1998 Jul 24; 94 (2): Following 271]. Cell 93: 705-716, 1998 Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594, 2000 Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M: Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79: 1469-1477, 1999 Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274: 10911-10915, 1999 Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495-1502, 1997 Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994 Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-4577, 1999 Pourtau J, Mirshahi F, Li H, Muraine M, Vincent L, Tedgui A, Vannier JP, Soria J, Vasse M, Soria C: Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin. MFEBS Lett 459: 453-457, 1999 Hull MA, Thomson JL, Hawkey CJ: Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 45: 529-536, 1999 Yamada M, Kawai M, Kawai Y, Mashima Y: The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 19: 300-304, 1999 Ji YS, Xu Q, Schmedtje JFJ: Hypoxia induces high-mobility-group protein I(Y), transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ Res 83: 295-304, 1998 Schmedtje JFJ, Ji YS, Liu WL, DuBois RN, Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997 Michiels C, Arnould T, Knott I, Dieu M, Remacle J: Stimulation of prostaglandin synthesis by human endothelial cells exposed to hypoxia. Am J Physiol 264: C866-C874, 1993 Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 359: 843-845, 1992 Liu Y, Cox SR, Morita T, Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res 77: 638-643, 1995 Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L: Ahypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 182: 1683-1693, 1995 Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May L, Stern D: Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem 270: 11463-11471, 1995 Karakurum M, Shreeniwas R, Chen J, Pinsky D, Yan SD, Anderson M, Sunouchi K, Major J, Hamilton T, Kuwabara K: Hypoxic induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest 93: 1564-1570, 1994 Tian H, McKnight SL, Russell DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997 Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-makers of tumor angiogenesis (review). Int J Mol Med 2: 715-719, 1998 Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000 Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B: Tumor induction of VEGF promoter activity in stromal cells. Cell 94: 715-725, 1998 Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M: Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 130: 641-649, 2000. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM: Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 39: 581-591, 1998 Hoper MM, Voelkel NF, Bates TO, Allard JD, Horan M, Shepherd D, Tuder RM: Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 17: 748-756, 1997 Rak J, Filmus J, Kerbel RS: Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis. Eur J Cancer 32A: 2438-2450, 1996 Gruber R, Nothegger G, Ho GM, Willheim M, Peterlik M: Differential stimulation by PGE(2) and calcemic hormones of IL-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun 270: 1080-1085, 2000 Singh A, Purohit A, Ghilchik MW, Reed MJ: The regulation of aromatase activity in breast fibroblasts: The role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer 6: 139-147, 1999 Hinson RM, Williams JA, Shacter E: Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 93: 4885-4890, 1996 Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741, 1996 Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995 Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y, Honn KV: Thromboxane A(2) regulation of endothelial cell migration, angiogenesis and tumor metastasis. Biochem Biophys Res Commun 267: 245-251, 2000 Herschman HR, Xie W, Reddy S: Inflammation, reproduction, cancer and all that. ::: The regulation and role of the inducible prostaglandin synthase. Bioessays 17: 1031-1037, 1995 Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125-140, 1996 Zachary I, Mathur A, Yla-Herttuala S, Martin J: Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 20: 1512-1520, 2000 He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB: Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274: 25130-25135, 1999 Krishnamurthy P, Bird IM, Sheppard C, Magness RR: Effects of angiogenic growth factors on endotheliumderived prostacyclin production by ovine uterine and placental arteries. Prostaglandins Other Lipid Mediat 57: 1-12, 1999 Satterwhite CM, Farrelly AM, Bradley ME: Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells. Am J Physiol 276: H1091-H1097, 1999 Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/ vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97: 99-107, 1998 Bicknell R, Vallee BL: Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2. Proc Natl Acad Sci USA 86: 1573-1577, 1989 Gurubhagavatula I, Amrani Y, Pratico D, Ruberg FL, Albelda SM, Panettieri RAJ: Engagement of human PECAM-1 (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release. J Clin Invest 101: 212-222, 1998 Gullino PM, Ziche M, Alessandri G: Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev 9: 239-251, 1990 Gullino PM: Prostaglandins and gangliosides of tumor microenvironment: Their role in angiogenesis. Acta Oncol 34: 439-441, 1995 Ziche M, Morbidelli L, Alessandri G, Gullino PM: Angiogenesis can be stimulated or repressed in vivo by a change in GM3: GD3 ganglioside ratio. Lab Invest 67: 711-715, 1992 Ziche M, Alessandri G, Gullino PM: Gangliosides promote the angiogenic response. Lab Invest 61: 629-634, 1989 Form DM, Auerbach R: PGE2 and angiogenesis. Proc Soc Exp Biol Med 172: 214-218, 1983 Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett 372: 83-87, 1995 Harada S, Rodan SB, Rodan GA: Expression and regulation of vascular endothelial growth factor in osteoblasts. Clin Orthop 76-80, 1995 Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, Rodan SB: Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 93: 2490-2496, 1994 Diaz-Flores L, Gutierrez R, Valladares F, Varela H, Perez M: Intense vascular sprouting from rat femoral vein induced by prostaglandins E1 and E2. Anat Rec 238: 68-76, 1994 Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL: The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81: 101-107, 1999 Sheng H, Shao J, MorrowJD, Beauchamp RD, DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998 Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K, Hori M: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061-G1067, 1998 Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249, 1998 Ren Y, Walker CDS, Deng J, Ruan KH, Kulmacz RJ: Topology of prostaglandin H synthase-1 in the endoplasmic reticulum membrane. Arch Biochem Biophys 323: 205-214, 1995 Otto JC, Smith WL: The orientation of prostaglandin endoperoxide synthases-1 and-2 in the endoplasmic reticulum. J Biol Chem 269: 19868-19875, 1994 Reiger MK, DeWitt DL, Schindler MS, Smith WL: Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells. Arch Biochem Biophys 301: 439-444, 1993 Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL: Different intracellular locations for prostaglandin endoperoxide H synthase-1 and-2. J Biol Chem 270: 10902-10908, 1995 Nor JE, Christensen J, Mooney DJ, Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154: 375-384, 1999 Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403, 2000 Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC, Sessa WC: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102-9105, 2000 Dimmeler S, Zeiher AM: Akt takes center stage in angiogenesis signaling. Circ Res 86: 4-5, 2000 Jiang BH, Zheng JZ, Aoki M, Vogt PK: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 97: 1749-1753, 2000 Hermann C, Assmus B, Urbich C, ZeiherAM, Dimmeler S: Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 20: 402-409, 2000 Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS: Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial. J Clin Pharmacol 40: 124-132, 2000 Clemett D, Goa KL: Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59: 957-980, 2000 Patrignani P: Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. Toxicol Lett 112-113: 493-498, 2000 Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 354: 2106-2111, 1999 Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, Isakson PC, Verburg KM, Yu SS, Zhao WW, Geis GS: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 282: 1921-1928, 1999 Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 21: 1688-1702, 1999 Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992 Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58: 5686-5689, 1998 Milas L, Kishi K, Hunter N, Mason K, Masferrer JL, Tofilon PJ: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91: 1501-1504, 1999 Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, Tofilon PJ, Milas L: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60: 1326-1331, 2000 Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000 Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24, 2000 Hanahan D, Bergers G, Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047, 2000 Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000 Stockbrugger RW: Nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer. Eur J Cancer Prev 8 Suppl 1: S21-S25, 1999 Fournier DB, Gordon GB: COX-2 and colon cancer: Potential targets for chemoprevention. J Cell Biochem Suppl 34: 97-102, 2000 Williams CRL, DuBois RN: The role of COX-2 in intestinal cancer. Ann NY Acad Sci 889: 72-83, 1999 Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, Shah JP, Edelstein D, Subbaramaiah K, Dannenberg AJ: Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann NY Acad Sci 889: 62-71, 1999 Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297, 2000 Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989 Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA, 93: 2002-2007, 1996 Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812, 1999